Atypical polypoid adenomyoma (APA) of the endometrium is a rare uterine lesion characterized by atypical endometrial glands and fibromuscular stroma that can cause severe abnormal uterine bleeding and secondary anemia. According to case reports published in medical literature including Cureus and the National Center for Biotechnology Information (NCBI) database, this uncommon condition primarily affects premenopausal women and requires careful histological evaluation to differentiate it from myoinvasive endometrioid adenocarcinoma, allowing patients to pursue fertility preservation through local resection rather than radical surgery.
Clinical Presentation and Diagnosis of Atypical Polypoid Adenomyoma
Atypical polypoid adenomyoma typically presents with symptoms such as abnormal uterine bleeding, recurrent hypermenorrhea, and associated secondary anemia. According to documentation in the NCBI database, a notable case involved a 45-year-old nulliparous woman who experienced abnormal bleeding starting in November 2019 following previous fertility treatments in 2016. Diagnostic evaluation through hysteroscopy on February 28, 2020, revealed a pedunculated polypoid lesion extending from the lower uterine body to the upper endocervix. Pathologists removed the mass via piecemeal hysteroscopic transcervical resection.
Macroscopically, APA specimens appear as grey, firm polypoid fragments. Microscopically, the lesion consists of atypical endometrial glands distributed haphazardly within a smooth muscle stroma. According to histological findings, these glands exhibit irregular contours, enlarged nuclei with thickened nuclear membranes, prominent nucleoli, and a loss of nuclear polarization. Frequent mitotic figures and diffuse squamous nonkeratinizing metaplasia, also known as morular metaplasia, frequently appear within the epithelial component.
Differential Diagnosis and Fertility Preservation Management
Distinguishing APA from myoinvasive endometrioid carcinoma remains one of the primary challenges for pathologists examining uterine corpus tumors. According to the World Health Organization (WHO) classification of mixed epithelial and mesenchymal tumors, APA shares architectural overlap with malignant lesions, making immunohistochemical markers essential for accurate diagnosis. Correct identification directly impacts clinical management, as patients diagnosed with APA can safely undergo local resection and potential repeat procedures for local recurrences while preserving reproductive potential, unlike women with myoinvasive adenocarcinoma who generally require definitive surgical staging.
Prognosis and Recurrence Considerations
While local resection offers a uterus-sparing alternative for premenopausal patients, clinical follow-up is critical due to the recurrence patterns of the lesion. According to peer-reviewed data from NCBI, APA has a documented tendency to recur locally after initial excision. Furthermore, the lesion is occasionally associated with or anticipates the development of atypical hyperplasia or concurrent endometrioid adenocarcinoma. Gynecologic specialists utilize specialized immunohistochemical staining for muscular and endometrial stromal markers to monitor residual disease and ensure patient safety during fertility-sparing management protocols.
Keep reading